Invex Therapeutics Ltd

Invex Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on developing treatments for neurological conditions and focused on developing treatments for neurological conditions. Its primary focus is Idiopathic Intracranial Hypertension (IIH), a condition of predominately overweight women of childbearing age, which can lead to disabling headaches and, in some patients, permanent vision loss. It has completed a Phase II trial. The Company’s lead program is the development of Presendin for IIH. Presendin is a once-per week, subcutaneous, sustained-release (SR) Exenatide microsphere formulation developed by Peptron, Inc. The Company is conducting a Phase III clinical trial (IIH EVOLVE) designed to meet the requirements for market approval of Presendin for the treatment of IIH in the European Union (EU), United Kingdom (UK) and Australia.